InnoCan Pharma Corporation (IP40)
XDUS
1.33
-0.02 (-1.48%)
Closed
Aug 24, 2026
Day's Range
1.331.35
52 wk Range
0.122012.58
Financial Statements - IP40 - InnoCan Pharma Corporation
Revenue
26.61M▼ 9.6%
Net Income
-341.00K▼ 30.2%Net Margin -1.3%
EBITDA
-1.21M▼ 0.1%
Free Cash Flow
479.00K▲ 130.1%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | 26.61M | 29.43M |
| Cost of Goods | 2.68M | 3.25M |
| Gross Profit | 23.93M | 26.18M |
 Operating Expense | - | - |
| Operating Income | -1.25M | -1.24M |
| Non-Operating Interest | - | - |
| Other Income Expense | 1.34M | 2.17M |
| Pre Tax Income | 85K | 919K |
| Income Tax | 426K | 1.18M |
| Net Income | -341K | -262K |
| EPS Basic | -0.25 | -0.65 |
| EPS Diluted | -0.25 | -0.65 |
| Basic Shares Outstanding | 4.47M | 4.30M |
| Diluted Shares Outstanding | 4.47M | 4.30M |
| Ebit | 88K | 926K |
| Ebitda | -1.21M | -1.21M |
| Net Income Continuous Operations | -341K | -262K |
| Minority Interests | -783K | -1.57M |
| Preferred Stock Dividends | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
